ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol

• Published in: BMC ophthalmology Vol. 11; no. 1; p. 1
• Main Authors: Bochmann, Frank, Kaufmann, Claude, Becht, Christoph N, Guber, Ivo, Kaiser, Michael, Bachmann, Lucas M, Thiel, Michael A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.01.2011; BioMed Central; BMC
• Subjects: Angiogenesis; Antibodies; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Binding sites; Care and treatment; Conjunctiva - surgery; Control; Cornea; Cytokines; Drug Administration Schedule; Drug dosages; Encapsulation; Eye; Eye lens; Fibroblasts; Follow-Up Studies; Glaucoma; Glaucoma - physiopathology; Glaucoma - surgery; Humans; Immunoglobulins; Immunotherapy; Intraocular Pressure; Lens Implantation, Intraocular; Macular degeneration; Metabolites; Metastasis; Mitomycin - therapeutic use; Mitomycin C; Monoclonal antibodies; Neovascularization; Ophthalmic Solutions; Ophthalmology; Patient outcomes; Patients; Phacoemulsification; Photography; Postoperative Period; Pressure; Ranibizumab; Research Design; Scars; Side effects; Study Protocol; Surgery; Sutures; Trabeculectomy; Treatment Outcome; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Wound Healing
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/1471-2415-11-1

Excessive wound healing, with scarring of the episcleral tissue or encapsulation of the filtering bleb is the main reason for failure in trabeculectomy. Ranibizumab, an inhibitor of the Vascular Endothelial Growth Factor (VEGF), is seen as a promising candidate to prevent or treat extensive wound healing. We describe the design of a two phased study, i) assessing the local tolerability and safety of topical ranibizumab and ii) assessing the efficacy of topical ranibizumab against placebo in patients who underwent trabeculectomy with mitomycin C combined with phacoemulsification and intra ocular lens (IOL) implantation. In the first phase five patients that had trabeculectomy with mitomycin C combined with phacoemulsification and IOL implantation will be treated with topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for one month. The treatment will be started at the first postoperative day. Patients will be assessed for local and systemic side effects using a standardised schedule. In the second phase, after successful completion of phase 1, consenting eligible patients who underwent trabeculectomy with mitomycin C combined with phacoemulsification and IOL implantation will be randomised to either receive topical ranibizumab eye drops (2 mg/ml) four times daily for 1 month or placebo (BSS 4x/d for 1 month). Patients will be reviewed weekly for 4 weeks until conjunctival sutures are removed. Further follow up examinations are planned after 3 and six months. Assessment of differences in the intraocular eye pressure will be considered primary, and bleb appearance/vascularisation using a standardized photography and the Moorfields bleb grading system, postoperative intraocular pressure and conjunctival wound healing problems will be considered secondary outcome parameters. Anti-VEGF-antibodies might be more effective in preventing scaring and might have fewer toxic side effects than the currently used anti-metabolites and may replace them in the long term.